The Kelch-like ECH-associated protein 1/nuclear factor erythroid-derived 2-like 2 (KEAP1-NRF2) system is a pivotal defense mechanism against oxidative and electrophilic stress. Although transient NRF2 activation in response to stress is beneficial for health, persistent NRF2 activation in cancer cells has deleterious effects on 
well as organismal levels. Many environmental stimuli disturb redox homeostasis and result in biomolecules undergoing chemical changes such as protein carbonylation, lipid peroxidation and nucleic acid oxidation, leading to functional alteration or impairment of biomolecules. The KEAP1-NRF2 system is an important defense mechanism against redox disturbances.
1 NRF2 is a potent transcription activator belonging to the Cap'n'Collar (CNC) transcription factor family, which is characterized by a unique CNC motif followed by a well-conserved basic region-leucine zipper (bZip) structure. Under normal conditions, NRF2 is constantly poly-ubiquitinated by the CUL3-KEAP1 E3 ubiquitin ligase complex and subjected to degradation by proteasomes. When cells are exposed to oxidative and/or electrophilic stress, highly reactive thiols in KEAP1 are directly modified, "Transient NRF2 activation"). [2] [3] [4] Appropriate interaction between KEAP1 and NRF2 is considered critical for efficient ubiquitination of NRF2, and modification of KEAP1 thiols by electrophiles is likely to induce conformational alterations in the overall structure of the CUL3-KEAP1-NRF2 complex and to suppress the ubiquitination of NRF2.
The physiological relevance of NRF2 has been shown by numerous studies using Nrf2-deficient mice and human cohort studies of SNP in the promoter region of the NRF2 gene. Nrf2-deficient mice are generally susceptible to redox disturbances and easily develop drug toxicity. 5, 6 Oxidative tissue damage after ischemia and reperfusion, including that resulting in noise-induced hearing loss, is effectively suppressed by NRF2 activation through its antioxidant function. 7 Further, NRF2 possesses potent anti-inflammatory activity and alleviates a variety of inflammatory conditions, including autoimmune diseases. 8, 9 In line with these protective roles of the KEAP1-NRF2 system, NRF2 activation effectively prevents chemical carcinogenesis by increasing antioxidant and detoxification capabilities. [10] [11] [12] [13] NRF2 activation in cancer-bearing hosts is also beneficial as a result of the fact that it potentiates anticancer immunity. NRF2 effectively inhibits the activity of MDSC and prevents apoptotic T reg cell-mediated immunosuppression by protecting T reg cells from apoptosis. [14] [15] [16] Thus, NRF2 activation in the host is beneficial as a result of its suppressive effect on cancer initiation and its anticancer-cell activity.
| ABERRANT ACTIVATION OF N RFAS A STRONG PROGNOSTIC FACTOR IN CANCER PATIENTS
In contrast to the protective roles described above, persistent activation of NRF2 at high levels in normal cells has deleterious effects.
Keap1-deficient mice die after weaning as a result of obstructive lesions in the upper digestive tract caused by epithelial hyperkeratosis. 17 Keap1 deficiency in the developing kidney causes polyuria with low osmolality and bilateral hydronephrosis. 18 Keap1 deficiency in bone marrow results in the exhaustion of hematopoietic stem cells.
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These deleterious effects are all canceled by Nrf2 disruption, indicating that excessive activation of NRF2 in normal cells is toxic and 56 RAS signal activation induces the recruitment of MYC to the NRF2 promoter and upregulates NRF2 transcription, which is suggested to enhance the tumorigenesis induced by the oncogenic KRAS mutant. 57 
| ESTABLISHMEN T OF N RF2-ADDICTED CANCER CELLS
Because NRF2 confers great advantages on cancer cells, including therapeutic resistance, increased antioxidant capacity and aggressive tumorigenic ability, cancer cells with NRF2 activation often develop "NRF2 addiction", which is one of the forms of non-oncogene addiction. This state has been shown in human cancer cell lines and mouse cancer models with abundant accumulation of NRF2 (Table 2) .
Although persistent activation of NRF2 confers growth and survival advantages on cancer cells, leading to NRF2 addiction, excessive activation of NRF2 in normal cells is rather toxic, as described in Section 2. These results imply that certain prerequisites, which are not fully understood, enable the establishment of NRF2-addicted cancers.
An important observation for understanding the dominant role of NRF2 in driving aggressive cell proliferation is that nuclear accumulation of NRF2 is greatly enhanced in the presence of proliferative signals. 63, 75, 76 Whereas NRF2 is trapped by the CUL3-KEAP1 complex in the cytoplasm and ubiquitinated for degradation, NRF2 is also ubiquitinated by the CUL1-bTrCP complex after being phosphorylated by GSK3. 77, 78 As GSK3 is phosphorylated by AKT and inacti- 27 whereas these triple mutations in the pancreas do not cause cancers but result in fibrosis instead. 80 These observations suggest that tissue-specific factors are likely to determine the prerequisites for NRF2-addicted cancer development. 
| CH ARACTERISTICS OF NRF2-ADD ICTED CANCER CE LLS

| FUTURE PERSPECTIVES OF DIAGN OSTIC AND THERAPEUTIC STRATEGIES FOR NRF2 -ADD ICTED CANCERS
Several NRF2 inhibitors have been reported for the treatment of NRF2-addicted cancers. 61, 62 For example, brusatol, which is a plantderived natural quassinoid, promotes poly-ubiquitination of NRF2, which reduces the NRF2 protein level without changing the transcription level of the NRF2 gene. 62 Another NRF2 inhibitor, halofuginone, was found to exert a chemosensitizing effect on NRF2-addicted cancer cells. 61 Halofuginone represses prolyl-tRNA synthetase activity leading to translational inhibition. NRF2 protein level is effectively reduced by halofuginone, which is consistent with a short half-life of the NRF2 protein.
New potential therapeutic targets of NRF2-addicted cancers are being identified in addition to NRF2 inhibitors ( 
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